Denali Therapeutics Inc.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
DNLI$19.85-2.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders' Equity
(In thousands, except share amounts)
| Common Stock · Additional Paid-in Capital · Accumulated Other Comprehensive Income (Loss) · Accumulated Deficit · Total Stockholders' Equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance at December 31, 2022 | 135,965,918 | $1,686 | $2,018,617 | $(6,886) | $(970,987) | $1,042,430 |
| Issuances under equity incentive plans | 1,232,526 | 12 | 17,808 | — | — | 17,820 |
| Vesting of restricted stock units | 1,187,054 | 13 | (13) | — | — | — |
| Stock-based compensation | — | — | 108,399 | — | — | 108,399 |
| Net loss | — | — | — | — | (145,224) | (145,224) |
| Other comprehensive income | — | — | — | 7,529 | — | 7,529 |
| Balance at December 31, 2023 | 138,385,498 | $1,711 | $2,144,811 | $643 | $(1,116,211) | $1,030,954 |
| Issuance of common stock and pre-funded warrants, net of issuance costs of $480 | 3,244,689 | 32 | 499,221 | — | — | 499,253 |
| Issuances under equity incentive plans | 1,288,609 | 13 | 17,376 | — | — | 17,389 |
| Vesting of restricted stock units | 1,302,190 | 12 | (12) | — | — | — |
| Stock-based compensation | — | — | 103,484 | — | — | 103,484 |
| Net loss | — | — | — | — | (422,773) | (422,773) |
| Other comprehensive income | — | — | — | 1,377 | — | 1,377 |
| Balance at December 31, 2024 | 144,220,986 | $1,768 | $2,764,880 | $2,020 | $(1,538,984) | $1,229,684 |
| Issuance of common stock and pre-funded warrants, net of issuance costs of $728 | 9,142,857 | 91 | 189,158 | — | — | 189,249 |
| Issuances under equity incentive plans | 1,368,573 | 14 | 8,445 | — | — | 8,459 |
| Vesting of restricted stock units | 1,449,761 | 15 | (15) | — | — | — |
| Stock-based compensation | — | — | 100,247 | — | — | 100,247 |
| Net loss | — | — | — | — | (512,540) | (512,540) |
| Other comprehensive loss | — | — | — | (1,338) | — | (1,338) |
| Balance at December 31, 2025 | 156,182,177 | $1,888 | $3,062,715 | $682 | $(2,051,524) | $1,013,761 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.